INTENSITY THERAPEUTICS, INC. Files 2023 Annual Report on Form 10-K

Ticker: INTS · Form: 10-K · Filed: Mar 14, 2024 · CIK: 1567264

Intensity Therapeutics, Inc. 10-K Filing Summary
FieldDetail
CompanyIntensity Therapeutics, Inc. (INTS)
Form Type10-K
Filed DateMar 14, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $246 billion
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Annual Report, Intensity Therapeutics, Biotechnology, SEC Filing

TL;DR

<b>INTENSITY THERAPEUTICS, INC. has filed its 2023 annual report (10-K) detailing its operations and financial standing.</b>

AI Summary

INTENSITY THERAPEUTICS, INC. (INTS) filed a Annual Report (10-K) with the SEC on March 14, 2024. INTENSITY THERAPEUTICS, INC. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is engaged in the Biological Products (No Diagnostic Substances) industry, SIC code 2836. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 61 Wilton Road, 3rd Floor, Westport, CT 06880. The report was filed on March 14, 2024.

Why It Matters

For investors and stakeholders tracking INTENSITY THERAPEUTICS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Intensity Therapeutics' financial performance, strategic initiatives, and risk factors for the fiscal year 2023, crucial for investors to assess the company's current health and future prospects. Understanding the details within this filing is essential for stakeholders to evaluate the company's position in the biotechnology sector, particularly concerning its product development and market strategy.

Risk Assessment

Risk Level: medium — INTENSITY THERAPEUTICS, INC. shows moderate risk based on this filing. The company's financial statements and operational details are presented in this 10-K, but specific financial performance metrics like revenue, net income, or debt levels are not detailed in the provided snippet, making a precise risk assessment difficult without further information.

Analyst Insight

Review the full 10-K filing to understand Intensity Therapeutics' financial health, product pipeline, and strategic direction for 2024.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Fiscal year end date)
  • 2024-03-14 — Filing Date (Date the 10-K was filed)
  • 2023-01-01 — Reporting Period Start (Start date of the reporting period)
  • 2023-12-31 — Reporting Period End (End date of the reporting period)

Key Players & Entities

  • INTENSITY THERAPEUTICS, INC. (company) — Filer name
  • 20231231 (date) — Conformed period of report
  • 20240314 (date) — Filed as of date
  • 0001567264 (company) — Central Index Key
  • 2836 (industry) — Standard Industrial Classification
  • DE (jurisdiction) — State of incorporation
  • 61 WILTON ROAD, 3RD FLOOR (address) — Business address street 1
  • WESTPORT (location) — Business address city

FAQ

When did INTENSITY THERAPEUTICS, INC. file this 10-K?

INTENSITY THERAPEUTICS, INC. filed this Annual Report (10-K) with the SEC on March 14, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by INTENSITY THERAPEUTICS, INC. (INTS).

Where can I read the original 10-K filing from INTENSITY THERAPEUTICS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INTENSITY THERAPEUTICS, INC..

What are the key takeaways from INTENSITY THERAPEUTICS, INC.'s 10-K?

INTENSITY THERAPEUTICS, INC. filed this 10-K on March 14, 2024. Key takeaways: INTENSITY THERAPEUTICS, INC. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The company is engaged in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.. The filing covers the period from January 1, 2023, to December 31, 2023..

Is INTENSITY THERAPEUTICS, INC. a risky investment based on this filing?

Based on this 10-K, INTENSITY THERAPEUTICS, INC. presents a moderate-risk profile. The company's financial statements and operational details are presented in this 10-K, but specific financial performance metrics like revenue, net income, or debt levels are not detailed in the provided snippet, making a precise risk assessment difficult without further information.

What should investors do after reading INTENSITY THERAPEUTICS, INC.'s 10-K?

Review the full 10-K filing to understand Intensity Therapeutics' financial health, product pipeline, and strategic direction for 2024. The overall sentiment from this filing is neutral.

How does INTENSITY THERAPEUTICS, INC. compare to its industry peers?

Intensity Therapeutics operates within the biotechnology sector, focusing on the development of biological products.

Are there regulatory concerns for INTENSITY THERAPEUTICS, INC.?

As a publicly traded company, Intensity Therapeutics is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

Industry Context

Intensity Therapeutics operates within the biotechnology sector, focusing on the development of biological products.

Regulatory Implications

As a publicly traded company, Intensity Therapeutics is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

What Investors Should Do

  1. Analyze the full financial statements within the 10-K to understand revenue, expenses, and profitability.
  2. Review the 'Risk Factors' section for potential challenges and uncertainties facing the company.
  3. Examine management's discussion and analysis (MD&A) for insights into strategic priorities and outlook.

Key Dates

  • 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
  • 2024-03-14: 10-K Filing Date — The date the annual report was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the annual report for the fiscal year ending December 31, 2023, providing updated financial and operational information compared to previous filings.

Filing Stats: 4,540 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2024-03-14 16:01:17

Key Financial Figures

  • $0.0001 — ange on Which Registered Common Stock, $0.0001 par value INTS The Nasdaq Stock Market
  • $246 billion — he United States is expected to rise to $246 billion by 2030. As healthcare costs in general

Filing Documents

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 48 Item 1B. Unresolved Staff Comments 76 Item 1C Cybersecurity 76 Item 2.

Properties

Properties 77 Item 3.

Legal Proceedings

Legal Proceedings 77 Item 4. Mine Safety Disclosures 77 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 78 Item 6. [Reserved] 79 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 79 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 86 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 86 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 86 Item 9A.

Controls and Procedures

Controls and Procedures 86 Item 9B. Other Information 87 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 87 Part III Item 10. Directors, Executive Officers and Corporate Governance 88 Item 11.

Executive Compensation

Executive Compensation 92 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 98 Item 13. Certain Relationships and Related Transactions, and Director Independence 100 Item 14. Principal Accountant Fees and Services 102 Part IV Item 15. Exhibits and Financial Statement Schedules 103 Item 16. Form 10-K Summary 104 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "will," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs; our need to raise additional funding before we can expect to generate any revenues from product sales; our plans to develop and commercialize our product candidates; the timing or likelihood of regulatory filings and approvals; the ability of our research to generate and advance additional product candidates; the implementation of our business mod

Business

Item 1. Business OVERVIEW Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx SM discovery platform. Intratumoral ("IT") treatment, or treatment designed to contain a drug inside a tumor without spreading to the rest of the body, has been an objective of clinicians since discovery of chemotherapeutic agents. The challenge with IT treatment approaches is that a tumor's lipophilic, high fat, dense and pressurized microenvironment is incompatible with and does not absorb water-based products. We believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments, which involve injecting aqueous drugs into a tumor without sufficient consideration of the tumor environment (regardless of the drug's mechanism or approach, i.e. the stimulation of an inflammatory response or efforts to attract immune cells into a hostile live tumor). Accordingly, there remains a continued unmet need for the development of direct IT therapies for solid tumors that provide high local killing efficacy coupled with nontoxic systemic anti-cancer effects. We believe we have created a product candidate with the necessary chemistry to overcome this local delivery challenge. Evidence shows the mechanism of tumor killing achieved by our drug candidate also leads to systemic immune activation and T-cell repertoire expansion in certain cancers. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and the other is soluble in fat or oils. When an amphiphilic compound is mixed with therapeutic agents, such as chemotherapies, the agents also become solubl

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.